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Abstract
Modification of cellular functions by overexpression of
genes is increasingly practised for research of signalling
pathways, but restricted by limitations of low efficiency.
We investigated whether the novel technique of magne-
tofection (MF) could enhance gene transfer to cultured
primary endothelial cells. MF of human umbilical vein
endothelial cells (HUVEC) increased transfection efficien-
cy of a luciferase reporter gene up to 360-fold compared
to various conventional transfection systems. In con-
trast, there was only an up to 1.6-fold increase in toxicity
caused by MF suggesting that the advantages of MF out-
balanced the increase in toxicity. MF efficiently increased
transfection efficiency using several commercially avail-
able cationic lipid transfection reagents and polyethyl-
eneimine (PEI). Using PEI, even confluent HUVEC could
be efficiently transfected to express luciferase activity.
Using a green fluorescent protein vector maximum per-
centages of transfected cells amounted up to 38.7%
while PEI without MF resulted in only 1.3% transfected
cells. Likewise, in porcine aortic endothelial cells MF
increased expression of a luciferase or a ß-galactosidase
reporter, reaching an efficiency of 37.5% of cells. MF is
an effective tool for pDNA transfection of endothelial
cells allowing high efficiencies. It may be of great use for
investigating protein function in cell culture experi-
ments.
Copyright © 2003 S. Karger AG, Basel
Introduction
Numerous modifications of gene delivery techniques
have been used to improve the efficiency of gene expres-
sion in mammalian cells [1–3]. High transfection efficien-
cy is important in approaches, where transfected gene
overexpression is used as a tool to study gene/protein
function as well as in therapeutic applications. Among the
tissues targeted, the vascular endothelium has a key role,
as treatment of endothelial dysfunction by gene transfer is
assumed to prevent vascular diseases such as hyperten-
sion, atherosclerosis, vascular thrombotic disease and
their complications [3–5]. Despite intensive efforts to
optimize gene delivery to endothelial cells of human and
other species [6–10], so far only low efficiencies of target
gene expression have been reported [7–9].
We have recently shown in several cell lines that cou-
pling of magnetic nanoparticles to gene vectors of any
kind results in a dramatic increase of the uptake of
these vectors and consequently, target protein expression
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[11]. Moreover, magnetofection (MF) allowed locally en-
hanced expression of ß-galactosidase activity in several
cell lines [11] and rapid and efficient transfer of small
nucleic acids into endothelial cells at low toxicity [12].
However, so far it has not been investigated whether this
technique could also succeed in enhancing efficiency of
nonviral vector-mediated gene expression in primary cells
like endothelial cells, which are well-known to be virtually
resistant to efficient transfection with pDNA [7–9]. If this
could be performed, a promising technique for in vivo
vascular gene delivery and a new tool for efficient re-
search would be at hand, which also could potentially
overcome many of the problems of in vivo gene transfer.
We, therefore, investigated, whether MF could be a feasi-
ble technique to increase the efficiency of gene transfer
into primary vascular cells like endothelial cells and
whether this influences cytotoxicity of transfections.
Methods
Endothelial Cell Culture
Human umbilical vein endothelial cells (HUVEC) were prepared
and grown to confluence in medium 199 (Sigma, Germany) supple-
mented with 20% newborn calf serum (NBCS, Biomol, Germany)
and 20% endothelial growth medium (Promocell, Germany) as pre-
viously described [13]. In addition, fresh porcine aortae were ob-
tained from the local slaughterhouse. Cells were harvested from aor-
tae as described [14] and grown to confluence in DMEM supple-
mented with glutamine (200 mM ), penicillin/streptomycin and 20%
fetal calf serum (FCS, Biomol). Only cells of the 1st to 3rd subpassage
were used for experiments.
Transfection of pDNA
On the day before MF, 5,000 or 10,000 HUVEC or porcine aor-
tic endothelial cells (PAEC) in a volume of 100 Ìl were seeded into
each well of a flat-bottom 96-well dish, to obtain cell layers of 50 or
90–100% confluence, respectively. To reach confluence states of
50% on the following day, 5,000 cells/well proved to be sufficient,
whilst seeding of 10,000 cells/well usually resulted in confluence
states of 95%. In some experiments, to reach highly confluent cell
layers, 50,000 cells/well were plated onto the cell culture dishes.
Before MF, medium was removed and 50 Ìl/well of serum-free
DMEM was added. For preparation of the MF mixture the desired
amount of pDNA was mixed with DMEM followed by the addition
of CombiMAG and gentle mixing by pipetting up and down 5
times (solution 1). The CombiMAG to pDNA ratio was 1:1 for
liposomal transfection reagents and 2:1 for polyethyleneimine
(PEI):DNA. For controls, DMEM was added as sham solution
instead of CombiMAG. Then the conventional transfection re-
agents or PEI were mixed with various amounts of DMEM (solu-
tion 2), to achieve the pDNA-transfection ratios recommended by
the manufacturers. PEI (25 kD) was added to a PEI:DNA N/P ratio
of 8. Solution 1 and 2 were mixed and incubated at room tempera-
ture for 30 min. Then 50 Ìl of each mixture were added per well,
resulting in the desired final concentration of pDNA/well. Subse-
quently, the cell culture plates were placed on Nd-Fe-B magnet-
ic plates (Chemicell, Berlin, Germany) for 15 min. After anoth-
er 4 h of incubation, medium was removed and new medium
added. Twenty-four hours after MF, the respective assays for detec-
tion of reporter expression were performed. Plasmids used were
p55pCMV-IVS-luc+ (firefly luciferase), EF·GFP (green fluorescent
protein), and pCMV-ß-gal [11].
Luciferase Activity
Twenty-four hours after transfection, cells were washed once with
PBS and then incubated with 100 Ìl of lysis buffer (0.1% Triton X-
100 in 250 mM Tris, pH 7.8). 10–50 Ìl of each cell lysate were trans-
ferred to black 96-well plates, mixed with 100 Ìl of luciferin buffer
[60 mM dithiothreitol, 10 mM magnesium sulfate, 1 mM ATP, 30 M
D(–)-luciferin, in 25 mM glycyl-glycine, pH 7.8] and assayed for bio-
luminescence using a TopCount instrument (Canberra Packard,
Groningen, The Netherlands). The protein content of the cell lysates
was determined using the BioRad protein assay adapted for use in a
96-well plate format. Specific luciferase activity in nanograms luci-
ferase per milligram of protein was calculated by a calibration curve,
which was obtained from luminescence of a serial dilution of lucifer-
ase (Roche, Mannheim, Germany).
Flow Cytometry
The efficiency of gene transfer of GFP was analyzed by flow
cytometry. Cells were washed once in PBS (containing calcium),
lysed by the addition of a trypsin solution for 2 min, followed by the
addition of PBS (without calcium) for another 2 min and fixation in
formalin (final concentration 2%). To assess cell viability in flow-
cytometric evaluations, cells were exposed to propidium iodide (PI;
500 ng/ml) for 30 min before harvesting and analyzing them. Fluo-
rescence intensity was analyzed using a FACScan flow cytometer
(Becton Dickinson). Data were analyzed using the CellQuest (Becton
Dickinson) software. Transfection efficiency was expressed as per-
cent of viable cells positively stained with GFP.
ß-Galactosidase Staining
For X-gal staining, cells were washed twice in PBS, fixed in 2%
formalin (w/v) solution and stained by addition of a solution contain-
ing 400 mM potassium ferricyanide, 400 mM potassium ferrocyan-
ide, 200 mM magnesium chloride and 1 mg/ml X-gal (Eurobio, Les
Ulis, France) for 1 h.
Toxicity
Toxicity was measured as LDH release using a CytoTox 96®
assay (Promega, Madison, Wisc., USA) following the manufacturer’s
instructions. Cells were treated as indicated and 50 Ìl of supernatants
mixed with 50 Ìl of the assay’s substrate mix and incubated at room
temperature for 30 min. The reaction was stopped by adding 50 Ìl of
acetic acid (1 M ) and absorption measured at 486 nm. For positive
controls, cells were treated with 1% Triton X-100 in Tyrode’s buffer
for 10 min. To assess the number of dead cells after this treatment,
trypan blue staining was performed. Maximum toxicity was set as the
LDH release caused by Triton X-100 (1%) treatment, while LDH
release from control cells was assumed not to be due to toxic causes.
The LDH release caused by the transfections then yielded a percent-
age of the toxicity caused by Triton treatment. LDH activity after
MF is expressed as n-fold increase over standard transfection.
Accordingly, the increase in toxicity caused by MF (table 1) in com-
parison to standard transfection is the ratio of toxicity caused by MF
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Fig. 1. MF increases luciferase expression in
cultured HUVEC. Transfected luciferase ac-
tivity was increased by MF using different
commercially available transfection reagents
(a, c, d) or DNA coupled to PEI (b). Vectors
were complexed to transMAGPEI by electro-
static interaction and salt-induced colloid
aggregation followed by incubation with the
indicated transfection reagents or PEI. Max-
imum luciferase activity of nonconfluent
cells (confluence state: 50–75%) was ob-
tained by MF using FuGENE with 500 ng of
DNA (a, n = 6). High efficiencies were also
reached for PEI (b, n = 6). Throughout most
DNA concentrations and different nonviral
transfection reagents (a: FuGENE, c: Lipo-
fectamine, n = 6, d: DMRIE, n = 6) MF ($)
was superior to conventional transfection
()). Numbers above bars represent fold in-
crease achieved by MF compared to conven-
tional nonviral transfection techniques.
and the toxicity of standard transfection. The increase in efficiency
by MF corrected for toxicity (table 1) is the ratio of increase in effi-
ciency and increase in toxicity caused by MF and is expressed as
n-fold.
Materials
Magnets and magnetic beads (CombiMAG) were from Chemicell
(Berlin, Germany). PEI (25 kD) was from Aldrich (Deisenhofen,
Germany), the Luciferase assay kit was purchased from Promega
(Germany) and 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside
(X-gal) was from Biotech Trade & Service (Germany).
Statistics
All data are expressed as means B standard deviation. The Stu-
dent’s t test was performed for all comparisons. For paired observa-
tions the paired t test was performed. An error probability level of
p ! 0.05 was considered significant.
Results
Transfection of pDNA into Subconfluent HUVEC
Several commercially available transfection reagents
were tested for MF compared with standard transfection
techniques. The vectors contained genes either encoding
luciferase (Luc+), GFP or ß-galactosidase (ß-gal). In addi-
tion to commercially available transfection reagents (Li-
Table 1. Transfection efficiency of a ß-galactosidase plasmid in
PAEC
pDNA
ng
FuGENE
standard TF
% of cells
MF
% of cells
PEI
standard TF
% of cells
MF
% of cells
62.5 9B5 30.1B7* – –
125 17.6B8 24.9B12 1.2B1 4.3B4**
250 18.6B7 36.6B13* 3.9B3 6.7B4**
500 19.6B6 20.1B7 5.8B3 14.7B5**
1,000 – – 6.3B5 37.5B7**
Percentages of cells (PAEC) staining positive for X-gal are shown.
Data representative of means B SD of 6 independent experiments,
* p 1 0.05, ** p ! 0.01 vs. standard transfection. TF = Transfection.
pofectamineTM, FuGENETM, DMRIE-CTM) pDNA com-
plexed with PEI was transfected. In all experiments trans-
fection conditions were identical except for the presence
or absence of magnetic beads.
Transfection efficiencies were assessed over a range of
different concentrations. Figure 1 summarizes mean effi-
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Fig. 2. MF enables gene transfer to con-
fluent HUVEC. Using MF, confluent cells
(confluence state 90–100%) exhibited high
expression of luciferase activity. Such MF
resulted in the highest overall luciferase ac-
tivity achieved independent of confluence
state (PEI with 1,000 ng DNA, n = 6).
Whereas conventional transfection did not
result in relevant luciferase activity in con-
fluent cells, several reagents such as PEI (a),
Lipofectamine (b), DMRIE (c), or FuGENE
(d), (n = 6 each) achieved notable levels of
activity of the reporter gene in combination
with MF. $ = MF; ) = conventional trans-
fection.
ciencies of diverse lipid transfection reagents and of PEI.
The highest luciferase activity following transfection of a
luc+-expressing plasmid was reached by MF of pDNA (at
500 ng/ well) in combination with FuGENE. MF in this
setup was 2.1-fold more effective than the respective con-
ventional transfection. The increases in efficiency, how-
ever, were only in part correlated with increasing pDNA
doses. Furthermore, there was not a simple shift in dose
dependency towards lower doses for the MF. In all cases,
except one where the MF and the standard protocol
accomplished a similar efficiency, maximum efficiencies
were reached by a transfection procedure using MF. Fur-
thermore, in many cases MF needed much lower doses of
pDNA to reach comparable results than the conventional
method. Similar results were obtained when using Gene-
PorterTM or EffecteneTM reagents combined with MF with
a luciferase plasmid (not shown).
Transfection of pDNA into Confluent HUVEC
We also tested the efficiency of the MF technique in
cells that had just reached confluency and are, therefore,
more suitable for designing experiments in which a more
physiological state of the endothelium is desired or in
which harvesting a certain amount of protein is planned
(confluency state approximately 95%), which are general-
ly thought not to promote expression of transfected
genes. Using conventional transfection, PEI yielded the
highest luciferase activity using high amounts of pDNA
(1,000 ng, 152 B 12 ng luciferase/mg protein). Using
CombiMAG the same concentration of pDNA reached a
luciferase activity of 1,306 B 69 ng luciferase/mg protein,
which not only represented an 8.6-fold increase of activity
compared to the standard protocol, but also the highest
overall luciferase activity reached in HUVEC irrespective
of the confluence state or transfection reagent used (n = 6,
p ! 0.01, fig. 2a). Of the other conventional reagents used
in confluent HUVEC, only Lipofectamine yielded a lu-
ciferase activity worth mentioning (250 ng pDNA, 50 B
5 ng luciferase/mg protein). The same setup with MF
reached an activity of 121 B 11 ng luciferase/mg protein
(2.4-fold increase, n = 6, p ! 0.01). Even more was reached
combining MF and Lipofectamine at pDNA levels of
125 ng pDNA/well (469 B 92 ng luciferase/mg protein,
217.9-fold increase vs. respective standard transfection,
n = 6, p ! 0.01, fig. 2b). Although FuGENE did not reach
the same efficiency in confluent cells as in subconfluent
HUVEC, in combination with MF it increased luciferase
activity severalfold over the whole range of pDNA con-
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centrations tested (fig. 2d, n = 6). Similar results were
obtained for DMRIE (fig. 2c, n = 6).
The combination that had reached the highest lucifer-
ase activities for MF (1,000 ng pDNA and MF) was also
tested for a plasmid coding for GFP. Using a flow-cyto-
metric analysis after previous PI staining to exclude dead
cells, a mean efficiency of 39 B 2% of living cells that
stained positive for GFP could be obtained (n = 6, count-
ing a total of 5,000 cells/experiment, p ! 0.01). Without
magnetic beads only 1 B 0.4% were reached by the same
setup. At 500 ng of pDNA in combination with PEI with
or without MF comparable differences were observed,
although at lower absolute efficiencies (fig. 3a, representa-
tive pictures: b–e). High efficiency, however, was reached
at considerable rates of cytotoxicity regardless of whether
the MF technique was used or not (33.4% staining posi-
tive for PI when using MF vs. 28.7% without MF).
Dependence of Transfection Efficiency on Confluency
State of HUVEC
To gain more insights into the optimal conditions for
transfection of endothelial cells we next investigated the
influence of the confluency state of the endothelial cells on
transfection efficiency. To this end, we transfected equal
amounts of pDNA (500 ng/well, see also above) of a GFP-
coding plasmid to cells in five different confluency states.
Cells were harvested and after plating them on new 24-
well dishes they were differently diluted so the confluency
state on the day of transfection altered from high con-
fluency (confluency reached on the same day as seeding
the cells, after seeding 50,000 cells/well) across different
levels of subconfluency (95%, 10,000 cells/well; 75%,
8,000 cells/well; 60%, 6,000 cells/well) to low confluency
(50%, 5,000 cells/well). Flow-cytometric analysis of cells,
48 h after transfection, revealed a linear correlation be-
tween the confluency state and the level of GFP-express-
ing cells, which decreased with increasing confluency
(fig. 3f). Cells at a low confluency state not only showed
least sensitivity to the toxicity of the procedure (24.3 B
1%), but were best to transfect reaching efficiency levels
of 16.5 B 0.5% compared to an efficiency of 4.0 B 0.1%
for highly confluent cells (n = 4 each, p ! 0.01). In addi-
tion, highly confluent cells also revealed the highest sensi-
Fig. 3. Efficiency of MF in HUVEC. a MF of a GFP-expressing vec-
tor achieved highest efficiency HUVEC when transMAGPEI-DNA
complexes were coupled to PEI. Flow-cytometric analysis revealed
maximum transfection efficiency of nearly 39% (n = 6, ) = conven-
tional transfection, $ = MF, numbers above bars: efficiency of GFP
expression in % of living, i.e. PI-positive cells, numbers in parenthe-
ses: of all cells). b–e Representative confocal images of GFP-express-
ing cells: MF + PEI 1,000 ng fluorescence (b), transmission (c),
PEI 1,000 ng without MF fluorescence (d), and transmission (e).
f Dependence of efficiency (bars) and toxicity (line) on the con-
fluence state of HUVEC at the time of transfection. There was a
linear correlation between toxicity (PI-positive cells) and increasing
confluency and an inverted linear correlation between increasing
confluency and efficiency of transfection (n = 4 each).
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Fig. 4. MF increases gene delivery into
PAEC. Similar results as in HUVEC were
found when MF was performed in PAEC
(confluence F75 %). When using FuGENE
(b, n = 3), PEI (c, n = 3), or DMRIETM
(a, n = 3), MF was able to increase luciferase
activity severalfold. However, when using
Lipofectamine (d, n = 3), neither MF nor
conventional transfection resulted in any ef-
ficiency worth mentioning. Similar results
were obtained when transfecting a ß-galacto-
sidase-coupled vector into PAEC. High effi-
ciencies were achieved for PEI (e: 1,000 ng
without MF, f: 1,000 ng with MF) or
FuGENE (g: 500 ng without MF, h: 500 ng
with MF). Images representative of 6 inde-
pendent experiments.
tivity to the toxicity of the procedure (50.2 B 3% PI-posi-
tive cells). In general experiments revealed that the lower
the confluency state of the cell layer was on the day of
transfection the higher was the efficiency and the lower
was the toxicity of the procedure (fig. 3f).
Specific Cytotoxicity of MF 
To gain deeper insights into the specific agent that
caused cytotoxicity after standard transfection or MF of
plasmidic vectors, LDH release of HUVEC cultured on
96-well culture dishes (confluence state 90–100%) was
Magnetofection of pDNA to Endothelial
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compared after conventional transfection of p55Luc+ us-
ing Lipofectamine and MF with Lipofectamine. The
LDH activity in cells 24 h after exposure to the respective
transfection reagent (as described in Methods) was com-
pared to the LDH activity in the supernatants of non-
transfected cells. For positive controls, cells were lysed by
exposing them to Triton X-100 1% for 10 min, which led
to 100% nonviable cells as confirmed by trypan blue
staining. At all concentrations tested, MF significantly
increased LDH activity when compared to exposure to
the respective standard transfection (fig. 5). Assuming
LDH release of untreated control cells to be 0% toxic and
Triton treatment to be 100% toxic, control transfections
using 62.5 ng/well killed 18 B 10% of cells compared to
29 B 7% using MF. Therefore, at 62.5 ng/well, MF
caused a 1.6-fold increase in toxicity (n = 11, p ! 0.01). At
125 ng/well this increase amounted to 2.3-fold (n = 5, p !
0.01), at 250 ng it was 1.6-fold (n = 5, p ! 0.01), and at
500 ng it was equal to the standard transfection using
Lipofectamine alone (MF: 35.6 B 0.8%, standard: 37.9 B
0.2%, n = 3 each, 0.9-fold, nonsignificant). Although there
were significant increases in cytotoxicity, this did not out-
weigh the advantageous efficiency caused by MF. When
calculating the relative increases caused by MF and cor-
recting the enhancement of luciferase expression for this
increase in toxicity, the resulting corrected efficiency still
revealed an up to 224-fold increase of luciferase activity
in magnetofected HUVEC (table 1).
Comparing the toxicity of the Lipofectamine-lucifer-
ase transfection with the one caused by the PEI-GFP
transfection (see above and fig. 3a–f) suggests that addi-
tion of the liposomal transfection reagent either/or the dif-
ferent plasmid, but not the amount of magnetic particles
which remained the same, may have caused the diverging
toxicity. To further investigate the actual component of
the transfection mixture that was responsible for the toxic
effect of the procedure, we continued to expose cells to
different combinations of the single components with and
without exposing them to a magnetic field. The results of
these experiments (shown in fig. 5b) reveal that none of
the single components alone, neither magnetic particles
(1 Ìg/ well) nor pure pDNA (500 ng/ well) nor both in
combination with or without a magnetic field (experi-
ments performed on 96-well plates), significantly in-
creased basal LDH release of HUVEC. Apparently, the
procedure only reached a toxic effect, when a transfection
reagent (such as Lipofectamine in luciferase experiments
or PEI in GFP experiments) was added so a successful
transfection was reached (fig. 3f, 5a).
Fig. 5. Lactate dehydrogenase (LDH) activity of endothelial cells fol-
lowing MF. a Comparison of LDH activity released into the superna-
tants of p55Luc+-transfected HUVEC (confluence 90–100%) using
Lipofectamine with (grey bars) or without (white bars) magnetic
force. LDH release is expressed as % of the release of control cells
(black bar). For positive controls all cells were killed using 10 min
exposure to Triton X-100 1% (dark grey bar, n = 5–11). b LDH
release of cells of similar confluency after 4 h of exposure to either
magnetic particles, pDNA, or PDNA bound to magnetic particles,
with or without exposure to a magnetic field (MF).
Transfection of pDNA into PAEC
As in HUVEC, MF was equally able to increase the
efficiency of transfection of a luciferase overexpressing
plasmid in PAEC (confluence 60–80%). The highest in-
crease in luciferase activity by MF observed in these cells
was 5.9-fold for 62.5 ng pDNA using DMRIE, MF
increased luciferase efficiency in any setup used, and
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Table 2. Transfection efficiency of p55Luc+ in HUVEC using Lipofectamine corrected for toxicity
pDNA
ng
Increase in
efficiency achieved
by MF, n-fold
Toxicity caused
by standard TF
LDH-release,
% triton treatment
Toxicity caused
by MF
LDH-release,
% triton treatment
Increase in
toxicity caused
by MF, n-fold
vs. standard TF
Increase in
efficiency caused
by MF corrected
for toxicity, n-fold
62.5 358.6
(control: 0.4 ng luciferase/
mg protein)
18B10 29B8 1.6 224.1
125 217.9
(control: 2.2 ng luciferase/
mg protein)
22B5 49B6 2.3 94.7
250 2.4
(control: 50 ng luciferase/
mg protein)
33B6 53B6 1.6 1.5
500 1.5
(control: 8.9 ng luciferase/
mg protein)
38B0 36B1 0.9 1.7
All data describe n-fold increase caused by MF in comparison to the respective standard method (equalling
100%). Data representative of 5–11 experiments.
achieved the highest overall efficiency. However, using
Lipofectamine, luciferase activity in PAEC could be not
be transfected at all without MF in our experiments, and
in this situation MF could not increase activity and there-
fore could also not lead to a satisfying result (all experi-
ments n = 3, for data see fig. 4a–d).
When transfecting a ß-galactosidase-coupled vector
into PAEC, MF again increased transfection efficiency.
High efficiencies were achieved for PEI (fig. 4e, f) or
FuGENE (fig. 4g, h), DMRIE yielded lower efficiencies.
Table 2 shows the transfection efficiencies expressed as
percent of cells positively staining for X-gal. In all setups,
MF yielded increased transfection efficiency when com-
pared to standard techniques, which reached a signifi-
cance for 250 and 62.5 ng of pDNA when using FuGENE,
or 1,000 or 500 ng of pDNA when using PEI (n = 6 for all
data). Again, 1,000 ng of PEI yielded maximum overall
efficiency (37.5 B 2% positively staining for X-gal).
Discussion
In this study we show that MF enhances transfection
efficiency of pDNA in endothelial cells, thought to be vir-
tually transfection resistant, of two different species. Fur-
thermore, MF allowed gene transfer into confluent cells,
and, under certain conditions, allows transfection in com-
bination with the cheap polycationic compound PEI,
rather than in combination with expensive, commer-
cially obtainable transfection mixtures. Although this is
achieved at an increase in cellular cytotoxicity, the advan-
tage of increased efficiency by far outweighs this en-
hanced cytotoxicity.
Among the primary cells targeted for gene delivery,
cultured HUVEC or PAEC, both cell types that are conve-
niently used, are an interesting target for transfection with
plasmid vectors, although they are relatively resistant to
effective gene delivery [7–9]. For many years, acceptable
efficiencies could only be reached by applying adenoviral
constructs [6, 15]. Recent data suggest, however, that
optimized electroporation techniques can also achieve
remarkable efficiencies of up to 40% [16]. Such levels of
efficiency represent the highest documented transfection
efficiencies for endothelial cells. However, electropora-
tion as well as adenoviral transfection are limited by sev-
eral problems. Electroporation requires expensive techni-
cal equipment and exerts high rates of cytotoxicity of 60%
of cells or more [16, 17]. Adenoviral gene delivery, on the
other hand, is restricted by a need for strict security mea-
sures. Furthermore, interpretation of experimentally
achieved results is difficult because any observed effect
might be caused by a simultaneous cellular expression of
unknown viral proteins. For such reasons, nonviral, lipo-
somal techniques for gene delivery into primary cells have
been intensely investigated [19]. We show here that MF
offers a simple, effective and cheap improvement of plas-
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midic gene delivery that results in an up to several hun-
dredfold increased efficiency in target gene expression in
HUVEC and PAEC. This increase in efficiency is accom-
panied by a significant increase of cellular toxicity caused
by the magnet-based protocol. However, magnetic parti-
cles or exposure of cells to magnetic fields do not appear
to cause this toxicity according to our data. Only transfec-
tion mixtures containing all compounds needed to
achieve satisfactory results (reagent, such as PEI or a
liposomal compound, pDNA, and magnetic nanobeads)
had toxic effects on cultured endothelial cells, suggesting
that either the addition of the transfection reagent or the
integration procedure of transfected pDNA into cellular
nuclei and the resulting protein expression take part in a
cytotoxic effect. Furthermore, we used a very sensitive
mode of assessment of toxicity. As control cells are
assumed to all be viable (0 toxicity) in our data, the results
obtained are likely to rather overestimate the toxicity of
the procedure. We have previously shown that using MF
high efficiency is already reached after 15 min and that
efficient short-term MF of oligonucleotides results in a
decreased cytotoxicity in HUVEC [11, 12]. However, in
order to compare toxicity and efficiency of MF with stan-
dard transfections, MF and control mixtures containing
the toxic cationic lipid reagents remained on cells for a
full 4 h in most experiments demonstrated here. After
removal of the magnet, this appeared to be the necessary
time to achieve satisfying results using the standard meth-
od. Considering that the effective amount of the transfec-
tion reagent mixture directly covering the cells was proba-
bly far enhanced in the MF group, an increased toxicity
caused by the increased lipid reagent concentration on the
cell surfaces seems likely. Therefore, the toxicity of the
method is probably even further overestimated. Nev-
ertheless, when adjusting the increase in toxicity to the
increase in efficiency, MF still exceeded the effectiveness
achieved by conventional cationic transfection several
hundred-fold.
Dose-response curves for increasing concentrations of
e.g. the luciferase plasmid used in our experiments do not
behave according to a linear correlation. In many cases,
there is rather a peak at one certain concentration, from
which on efficiency cannot be further enhanced by in-
creasing pDNA doses, which is probably due to prevailing
toxicity. This rising toxicity is caused by the use of higher
amounts of transfection reagent for higher doses of
pDNA. Therefore, dose-response curves obtained for one
transfection reagent or plasmid may not simply be confer-
red to another one, as shown by the different results
depending on transfection reagent using a luciferase plas-
mid. Thus, this study outlines the importance of perform-
ing extensive dose-response tests before using a reagent
with a special plasmid to transfect endothelial cells.
Although the transfection efficiency showed great di-
vergence depending on the transfection reagents used and
the confluence state of the HUVEC, MF significantly
improved transfection success in 34 out of 40 transfection
protocols in our study. FuGENE and simple complexing
of pDNA with PEI without further use of a liposomal
reagent were most effective in nonconfluent cells, but only
PEI, a small cationic molecule, in combination with MF
was similarly successful for confluent cells. However, the
confluency state of cells remains an important aspect for
planning efficient plasmid transfection, as we could ob-
serve that not only did the efficiency of MF decrease, but
also the toxicity of the procedure rose with increasing con-
fluency of endothelial cell layers. It remains to be men-
tioned, however, that efficiency in terms of percent of
cells expressing the transfected protein or enzyme, but
also the level of activity of this target is a desirable target.
Especially in transfections of a luciferase-encoding plas-
mid, where assessment of the success of the procedures is
not expressed as percent of transfected cells, but rather as
activity of the transfected enzyme, lower percentages of
expressing cells may still reveal high enzymatic activity.
MF furthermore succeeded in lowering the amount of
DNA needed to achieve an efficient procedure in 9 out of
12 applications of different combinations of transfection
reagent with cell type.
The mechanism of cellular uptake of the magnetic
bead-coupled pDNAs still remains to be revealed. The
increased effectiveness could simply be due to an in-
creased effective concentration of pDNA at the outer cel-
lular membrane. In vitro, an increase of an effective con-
centration at the outer cellular membrane could perhaps
also be reached by other means such as increasing pDNA
concentrations or by centrifugation of transfection com-
plexes onto cells. However, we have previously observed
that centrifugation of pDNA onto several cell lines cannot
equal the effect gained by MF [11], and increasing pDNA
and with it the concentrations of the transfection reagent
goes along with enhanced cytotoxicity. Notably, centrifu-
gation is also not applicable in vivo.
The advantages of MF and the finding that it is an easy
and effective technique to transfect endothelial cells give
rise to expectations as to its possible application in vivo.
The promising scenario of exerting a magnetic field only
to specific sites of an organism, thereby targeting plasmid
vectors to this site, is nourished by the short time needed
for effective transfection, as previously shown in certain
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cell lines [11] or endothelial cells, which altogether in-
creases the likeliness of a successful therapeutic interven-
tion. Especially in cardiovascular therapy enormous ef-
forts have been put into such site-directed therapy [5, 20,
21]. For example, a catheter-based coronary angioplastic
therapy, which has emerged as state of the art treatment
for occlusive cardiovascular disease [3, 21], could be
effectively supplemented by MF. Similar approaches
could be used for peripheral vascular disease, which is
already the subject of clinical gene therapy studies.
However, a number of points remain unresolved and
will be the subject of future investigations. These include
the question of whether a formulation of transfection
reagents can be found that minimizes the immunologic
responses caused by all commonly used cationic liposo-
mal transfection reagents. One key towards a solution of
such problems might be the finding that only in combina-
tion with PEI, a simple small cationic molecule, efficient
expression of luciferase activity could be reached in con-
fluent HUVEC. In this context, it is notable that the mean
activity reached in these experiments exceeded the maxi-
mum activity reached by any formulation in noncon-
fluent cells.
In summary, the feasibility and high effectiveness of
magnet-based transfection of endothelial cells should al-
low simple application and important advantages in ex-
perimental cellular investigation, and might be an impor-
tant step in enhancing the likeliness of reasonable in vivo
vascular gene transfer, which so far is not at hand.
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